Quantcast
Home > Quotes > ONVO

Organovo Holdings, Inc. Common Stock (ONVO) Quote & Summary Data

ONVO 
$1.32
*  
0.05
3.65%
Get ONVO Alerts
*Delayed - data as of Jul. 19, 2018  -  Find a broker to begin trading ONVO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 1.40 / $ 1.32
Share Volume
742,793
50 Day Avg. Daily Volume
1,240,443
Previous Close
$ 1.37
52 Week High / Low
$ 2.48 / $ 0.911
Market Cap
146,687,145
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
742,793
50 Day Avg. Daily Volume:
1,240,443

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.33

Trading Range

The current last sale of $1.32 is 44.90% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.40 $ 2.48
 Low: $ 1.32 $ 0.911

Company Description (as filed with the SEC)

Organovo Holdings, Inc. ("Organovo Holdings," "we," "us," "our," "the Company" and "our Company") is a biotechnology company pioneering a unique set of therapeutic and drug profiling capabilities based on its revolutionary ability to 3D bioprint tissues that emulate human biology and disease. We are developing in vivo liver tissues to treat a range of rare, life-threatening diseases, for which there are few current treatment options other than organ transplantation. Our first program, which focuses on a rare disease known as Alpha-1-antitrypsin deficiency ("A1AT"), received the U.S. Food and Drug Administration's ("FDA") orphan drug designation in December 2017 and is targeted for an Initial New Drug Application ("IND") filing in calendar-year 2020.  ... More ...  

Risk Grade

Where does ONVO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.37
Open Date:
Jul. 19, 2018
Close Price:
$ 1.32
Close Date:
Jul. 19, 2018

Consensus Recommendation

Analyst Info